表紙:インドの医薬品市場の将来予測 (2019~2029年)
市場調査レポート
商品コード
346223

インドの医薬品市場の将来予測 (2019~2029年)

Indian Pharmaceutical Market Forecast 2019-2029

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 212 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=158.33円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

インドの医薬品市場の将来予測 (2019~2029年)
出版日: 2019年05月09日
発行: Visiongain Ltd
ページ情報: 英文 212 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インドの医薬品市場は、2018年に288億米ドルにの規模に達し、さらに2019~2024年に16.6%のCAGR (複合年間成長率) で成長し続ける見通しです。特に、心血管疾患や感染症の治療薬の需要が今後大きく増加する、見られています。

当レポートでは、インドの医薬品市場について調査分析し、市場の基本構造や背景事情、収益動向の予測、主要企業の評価、促進要因・抑制要因、見通しなど、体系的な情報を提供しています。

第1章 レポートの概要

第2章 インドの医療:概要

  • インド:人口統計指標の概要
  • インドの医療制度:概要
    • Rashtriya Swasthya Bima Yojana:最底辺の労働者向け医療保険の提供
  • インドの医療費の分析

第3章 インドの医薬品の規制体制

  • 監督官庁
    • 医療・家庭福祉省 (MoHFW)
    • 化学製品・肥料省 (MoC&F)
  • 政府の関連機関
  • インドの医薬品市場向け法令・規制:一覧
  • 市場アクセス
    • 医療制度
    • HTA (Health Technology Assessment) の現状
    • 薬価動向
    • 医薬品の医療費償還

第4章 インドの医薬品市場:議論と予測

  • 世界で3番目に大きな市場
  • 市場収益額の予測値 (総額、今後12年間分)

第5章 インド国内の医療ニーズ

  • 各種疾患の有病者数 (今後11年間分)
  • 各種疾患の発症件数 (今後11年間分)
  • 各種疾患の死亡率 (今後11年間分)
    • インド国内の主な死因
    • 主な死因:死亡率の予測 (今後11年間分)

第5章 インドの医薬品市場:主な治療領域

  • 主な治療領域:概要
  • 市場予測:主な治療領域別 (今後11年間分)
  • 感染症治療薬
    • 市場予測 (今後11年間分)
      • 下痢
      • 下気道感染症
      • 結核
      • マラリア
      • HIV
    • 市場促進・抑制要因
  • 心血管疾患治療薬
  • 胃腸疾患治療薬
  • 呼吸器疾患治療薬
  • 疼痛緩和薬/鎮痛剤
  • 糖尿病治療薬
  • ビタミン剤/ミネラル/栄養剤
  • 皮膚病治療薬
  • 中枢神経系 (CNS) 疾患治療薬
  • 婦人科疾患治療薬
  • その他の疾患の治療薬

第7章 インドの医薬品市場:主な薬剤の種類

  • インド市場における医薬品の種類:概要
  • 主な種類の医薬品の成長率予測 (今後11年間分)
  • ジェネリック医薬品 - インド市場の大半を占める存在
    • 市場予測 (今後11年間分)
    • 市場促進・抑制要因、など
  • OTC医薬品 (市販薬)
  • 特許医薬品
  • バイオシミラー医薬品

第8章 インドの医薬品市場の代表的企業

  • インドの医薬品市場:概要
    • インドの医薬品関連の特許法と、大手製薬企業にたいする影響力
  • インド国内の製薬企業上位50社
  • Sun Pharmaceuticals Industries Limited
    • 業績動向 (過去10年間分)
    • 事業展開/資本取引動向
  • Abbott Healthcare Private Limited (Abbott India)
  • Cipla Ltd.
  • Cadila Healthcare Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer Limited., India
  • Lupin
  • Sanofi India Limited
  • Intas Pharmaceuticals Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited

第9章 インドの医薬品市場の定性分析

  • インドの医薬品市場:促進・抑制要因
  • インドの医薬品市場のSWOT分析
  • 強み
    • 医療制度への投資拡大
    • 疾病負荷・GDPの増大
    • インドの総人口:2030年には世界最大となる
    • 製薬産業の外注先として有望なインド
  • 弱み
    • 厳格な価格規制による市場への悪影響
    • 貧弱な医療インフラによる、潜在的市場の縮小
    • 競争激化に伴う薬価の下落
  • 機会
    • 世界規模でのジェネリック医薬品の需要増加
    • 国家農村健康ミッション (NRHM):農村部の医療アクセスの改善
    • 多国籍企業 (MNC) による巨額の投資の見通し
    • 革新的なバイオテクノロジー部門:特許満了を好機として躍進
  • 脅威
    • ジェネリック医薬品:他の低コスト輸出国の台頭
    • インド政府は今後も医療費の増額傾向を維持するのか?
    • 当局からの近年の警告と輸出禁止令:製薬企業の自信喪失
  • ポーターのファイブフォース分析
    • 企業間競争 (高)
    • 新規参入企業の脅威 (低)
    • サプライヤーの交渉力 (中)
    • バイヤーの交渉力 (高)
    • 代替製品の脅威 (低)

第10章 結論

  • インドの医薬品市場:世界市場でのシェアの拡大
  • 慢性疾患患者の急増
  • 市場促進要因
  • 市場抑制要因
  • 分析結果

第11章 用語一覧

図表

List of Tables

  • Table 4.1 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Table 5.2 Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014
  • Table 5.3 Causes of Death in India by World Ranking, 2014
  • Table 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2018, 2024, 2029
  • Table 6.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2018-2029
  • Table 6.3 The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.4 The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.5 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.6 The Indian Respiratory Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.7 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.8 Indian Diabetes Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.9 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.10 Indian Dermatological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.11 Indian CNS Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.12 Indian Gynaecological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.13 Indian Other Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2019, 2024 and 2029
  • Table 7.2 Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2019-2029
  • Table 7.3 Indian Generic Drugs Market: Revenue ($bn), AGR (%) and CAGR (%) 2018-2029
  • Table 7.4 Indian OTC Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.5 Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.6 Selected Biosimilar Therapeutics on the Indian Market, 2018
  • Table 7.7 Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.8 Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028
  • Table 7.9 Selected Late-Stage Biosimilar Pipeline Products, 2015
  • Table 8.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs. m), Revenue ($m) and Market Share (%), 2017
  • Table 8.2 Sun Pharmaceuticals: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Business Area, FY 2017
  • Table 8.3 Sun Pharmaceuticals: Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.4 Sun Pharmaceuticals: M&A Activity, 1997-2016
  • Table 8.5 Abbott India: Market Share (%) and Market Rank of Key Brands
  • Table 8.6 Abbott India: Revenue (Rs. m), AGR (%) and CAGR (%), 2006-2017
  • Table 8.7 Cipla: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.8 Cipla: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2017
  • Table 8.9 Cadila Healthcare Ltd.: Total Revenue (Rs. m), Total Revenue ($m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.10 Cadila Healthcare Ltd.: Revenue (Rs.m) and Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.11 GlaxoSmithKline India: Key Products in the Indian Market, 2017
  • Table 8.12 GlaxoSmithKline India Total Revenue (Rs. m), AGR (%) and CAGR (%), 2007-2017
  • Table 8.13 Pfizer India: Leading Brands on the Indian Market 2017
  • Table 8.14 Pfizer India: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.15 Lupin: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.16 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.17 Sanofi India Limited: Major Products,2017
  • Table 8.18 Sanofi India Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.19 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Domestic Segment, 2017
  • Table 8.20 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Branded drugs, 2017
  • Table 8.21 Sanofi India Limited: Revenue (Rs. m), and Revenue Share (%) by Geographical Area, 2017
  • Table 8.22 Intas Pharmaceuticals Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.23 Dr. Reddy's Laboratories Ltd: Major Products,2017
  • Table 8.24 Dr. Reddy's Laboratories Ltd: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.25 Dr. Reddy's Laboratories Ltd: Revenue (Rs. m), and Revenue Share (%) by Business Segment, 2017
  • Table 8.26 Dr. Reddy's Laboratories Ltd: Revenue (Rs.m), and Revenue Share (%) by Geographical Area, 2017
  • Table 8.27 Glenmark Pharmaceuticals Limited: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 9.1 SWOT Analysis of the Indian Pharmaceuticals Market

List of Figures

  • Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets
  • Figure 2.1 Indian Population: Rural and Urban (Mn),1960-2020
  • Figure 2.2 Indian Population: Total (Mn) and Annual Population Growth Rate (%), 1960-2020
  • Figure 2.3 Indian GDP ($bn) and Growth Rate (%), 2010-2020
  • Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2008-2020
  • Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2014
  • Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2008-2014
  • Figure 3.1 National Regulatory Bodies Regulating the Indian Pharmaceutical Market
  • Figure 4.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Figure 6.1 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2018
  • Figure 6.2 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2024
  • Figure 6.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 6.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
  • Figure 6.6 Infectious Diseases Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.8 Cardiovascular Diseases Therapeutics Market in India: Drivers and Restraints
  • Figure 6.9 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.10 Gastro-intestinal Therapeutics Market in India: Drivers and Restraints
  • Figure 6.11 Indian Respiratory Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.12 Respiratory Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.13 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.14 Pain Relief/Analgesics Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.15 Indian Diabetes Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.16 Diabetes Therapeutics Market in India: Drivers and Restraints
  • Figure 6.17 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.18 Vitamins / Minerals / Nutrients Therapeutics Market in India: Drivers and Restraints
  • Figure 6.19 Indian Dermatological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.20 Dermatological Therapeutics Market in India: Drivers and Restraints
  • Figure 6.21 Indian CNS Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.22 CNS Therapeutics Market in India: Drivers and Restraints
  • Figure 6.23 Indian Gynaecological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.24 Gynaecological Therapeutics Market in India: Drivers and Restraints
  • Figure 6.25 Indian Other Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2019
  • Figure 7.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2024
  • Figure 7.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 7.4 Indian Generic Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.5 Generic Drugs Market in India: Drivers and Restraints
  • Figure 7.6 Indian OTC Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.7 OTC Drugs Market in India: Drivers and Restraints
  • Figure 7.8 Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.9 Patented Drugs Market in India: Drivers and Restraints
  • Figure 7.10 Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.11 Biosimilar Drug Market in India: Drivers and Restraints
  • Figure 8.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, FY 2017
  • Figure 8.2 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.3 Abbott India: Revenue (Rs. m) and AGR (%), 2006-2017
  • Figure 8.4 Cipla Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 8.5 Cadila Healthcare Ltd.: Revenue Share (%), by Business Area, 2017
  • Figure 8.6 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2007-2017
  • Figure 8.7 Pfizer India: Revenue (Rs.m) and AGR (%), 2007-2016
  • Figure 8.8 Lupin: Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 8.9 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Figure 8.10 Sanofi India Limited: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.11 Sanofi India Limited: Revenue Distribution by Business Segments, 2017
  • Figure 8.12 Sanofi India Limited: Revenue Distribution by Domestic Segments, 2017
  • Figure 8.13 Sanofi India Limited: Revenue Distribution by Geographical Area, 2017
  • Figure 8.14 Intas Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.15 Dr. Reddy's Laboratories Ltd: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.16 Dr. Reddy's Laboratories Ltd: Revenue Distribution by Business Segments, 2017
  • Figure 8.17 Dr. Reddy's Laboratories Ltd: Global Generics Segment Revenue Distribution by Geographical Area, 2017
  • Figure 8.18 Glenmark Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2007-2017
  • Figure 8.19 Glenmark Pharmaceuticals Limited: Revenue Distribution by Geographical Area, 2017
  • Figure 9.1 Indian Pharmaceuticals Market: Drivers and Restraints
  • Figure 9.2 Porter's Five Forces Analysis of the Indian Pharmaceuticals Market

COMPANIES LISTED:

  • Abbott India
  • Able Labs
  • Ajanta Pharma Ltd
  • Akumentis Healthcare Ltd
  • Albert David Ltd
  • Alembic
  • Alkem
  • Almirall
  • Amgen
  • Apex Laboratories Pvt. Ltd
  • Aristo Pharma
  • Ascendis Pharma
  • AstraZeneca
  • Aventis Pharma Limited
  • Bayer
  • Bharat Serums
  • Biocon Ltd
  • Biosintez
  • Blue Cross Laboratories Ltd.
  • Cadila Healthcare Ltd.
  • Caraco
  • Chattem Chemicals, Inc.
  • Cipla
  • Claris Lifesciences
  • Daiichi Sankyo
  • Divis Laboratories
  • Dr. Reddy's Laboratories
  • DUSA Pharma, Inc.
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Emcare
  • Eris Lifesciences
  • Exelan
  • FDC
  • Fourrts (India) Laboratories Pvt, Ltd
  • Franco India
  • GlaxoSmithKline India
  • Glenmark Pharma
  • GSK India
  • Heinz India
  • Helsinn Group
  • Hetero Drugs Ltd
  • Hoechst India Limited
  • Hoechst Marion Roussel Limited
  • Hoechst Pharmaceuticals Private Limited
  • Indoco
  • Indi Pharma Pvt. Ltd.
  • InSite Vision
  • Intas Pharma
  • InvaGen
  • Ipca Laboratories
  • Janssen
  • JB Chemicals
  • JSC Biosintez
  • Lonza
  • Lupin
  • Macleods
  • MannKind Corporation
  • Medley Pharmaceuticals Ltd
  • MedproPhamaceutica (Pty) Ltd
  • Megafine Pharma
  • Merck KGaA
  • Meyer Organics
  • Micro Labs
  • MSD Pharma
  • Natco
  • Novartis India
  • Novo Nordisk
  • Odomzo
  • Pfizer India
  • Pharmalucence
  • Piramal Healthcare
  • Pola Pharma, Inc.
  • Ranbaxy
  • Raptakos, Brett & Co. Ltd
  • Roche Pharma India
  • Sandoz, Novartis Division
  • Sanofi India
  • Seciera
  • Sun Pharmaceuticals
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals (Pty)Ltd
  • The Himalaya Drug Company
  • Torrent Pharma
  • True North
  • Unichem
  • URL's
  • USV
  • Wallace Pharmaceuticals
  • Win-Medicare
  • Wockhardt
  • Wockhardt
  • Zydus Wellness Ltd

List of Organizations Mentioned in the Report:

  • Australia's TGA (Therapeutic Goods Administration)
  • Central Drugs Standard Control Organisation
  • Competition Commission of India (CCI)
  • Dr. M.G.R. Medical University (TNMGRMU)
  • Drug Consultative Committee
  • Drug Controller General of India
  • Medical Council of India
  • MHLW (Ministry of Health, Labour and Welfare)
  • MHRA (Medicines & Healthcare Products Regulatory Agency)
  • Ministry of Chemicals & Fertilisers
  • Ministry of Health and Family Welfare
  • National AIDS Control Organisation (NACO)
  • National Pharmaceutical Pricing Authority
  • Organisation for Economic Co-operation and Development (OECD)
  • State Food and Drug Administrations
  • The Joint United Nations Programme on HIV/AIDS (UNAIDS)
  • US Federal Trade Commission (FTC)
  • World Health Organization (WHO)
目次
Product Code: PHA0419

The Indian pharmaceuticals market is estimated to have reach $28.8bn in 2018 and is expected to grow at a CAGR of 16.6% in the first half of the forecast period. The market for cardiovascular medication is the fastest growing segment of the Indian pharmaceutical market, followed by the anti-infective segment.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 212-page report you will receive 121 charts - all unavailable elsewhere.

The 212-page report provides clear detailed insight into the Indian Pharmaceutical Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Indian Pharmaceuticals Market forecasts from 2019-2029

Revenue forecasts for the leading therapeutic areas in India from 2019-2029:

  • Anti-Infectives Therapeutics
  • Cardiovascular Therapeutics
  • Dermatological Therapeutics
  • Diabetes Therapeutics
  • Gastrointestinal Therapeutics
  • Gynaecology Therapeutics
  • CNS Therapeutics
  • Pain Relief/Analgesics Therapeutics
  • Respiratory Therapeutics
  • Vitamins/Minerals/Nutrients Therapeutics
  • Other Therapeutics

This report also discusses factors that drive and restrain these submarkets.

Revenue forecasts for the leading drug types in India from 2019-2029:

  • Generic Drugs
  • Over-the-Counter (OTC) Drugs
  • Patented Drugs
  • Biosimilar Drugs

This report also discusses factors that drive and restrain these submarkets.

Profiles and discusses the leading companies in the Indian pharmaceutical market:

  • Abbott Healthcare Private Limited (Abbott India)
  • Cadila Healthcare Limited
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Limited
  • Lupin
  • Pfizer Limited
  • Sanofi India Limited
  • Sun Pharmaceuticals Industries Limited

(Revenues are provided for those companies whose financial information is available on the public domain)

  • Analysis of the drivers and restraints of the Indian Pharmaceutical market
  • The report also discusses the Porter's Five Forces Analysis and SWOT Analysis of the Indian Pharmaceuticals Market

This report also discusses:

  • Indian healthcare system and Indian healthcare expenditure
  • Indian pharmaceutical regulatory framework, laws & regulations, market access, regulatory bodies
  • Disease prevalence and incidence in India, disease mortality rates in India, top causes of death in India, mortality projections from 2019-2029

What this report provides:

  • The Indian pharmaceutical market forecasts and analysis from 2019 to 2029
  • Analysis and forecasts for the Indian pharmaceutical submarkets from 2019 to 2029
  • Profiles of the leading companies operating within the Indian pharmaceutical industry
  • SWOT analysis and Porter's five forces analysis of the major strengths and weaknesses of the Indian pharmaceutical market together with the opportunities available and the key threats faced

Visiongain's study is intended for anyone requiring commercial analyses for the Indian Pharmaceuticals Market. You find data, trends and predictions.

Buy our report today Indian Pharmaceutical Market Forecast 2019-2029: Infectious Disease, Cardiovascular, Gastrointestinal, Respiratory, Pain Relief / Analgesics, Diabetes, Vitamins/ Minerals/ Nutrients, Dermatology, CNS, Gynaecology, Generic, OTC, Patented, Biosimilar, Leading Companies’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 The Indian Pharmaceutical Market Overview
  • 1.2 Indian Pharmaceutical Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Indian Healthcare: Overview

  • 2.1 India: Demographic Indicators Overview
  • 2.2 Indian Healthcare System: Overview
    • 2.2.1 Rashtriya Swasthya Bima Yojana - Bringing Healthcare Coverage to India's Poorest Workers
  • 2.3 Analysis of India's Healthcare Expenditure

3. Indian Pharmaceutical Regulatory Framework

  • 3.1 National Regulatory Bodies
    • 3.1.1 Ministry of Health & Family Welfare (MoHFW)
    • 3.1.2 Ministry of Chemicals and Fertilizers (MoC&F)
  • 3.2 State Regulatory Bodies (State Food and Drug Administrations (FDAs)
  • 3.3 Laws & Regulations for Indian Pharmaceutical Market
    • 3.3.1 The Drugs and Cosmetics Act, 1940
    • 3.3.2 The Pharmacy Act, 1948
    • 3.3.3 The Drugs & Magic Remedies Act, 1954
    • 3.3.4 The Narcotic Drugs and Psychotropic Substances Act, (NDPS)1985
    • 3.3.5 The Medicinal and Toilet Preparations Act, 1956
    • 3.3.6 The Drugs Price Control Order (DPCO), 1995
    • 3.3.7 Indian Patent Act 1970
    • 3.3.8 The Drugs Price Control Order (DPCO), 2013
    • 3.3.9 Good Clinical Practices (GCP)
    • 3.3.10 Good Laboratory Practices (GLP)
  • 3.4 Market Access
    • 3.4.1 Healthcare System
    • 3.4.2 Status of Health Technology Assessment (HTA)
    • 3.4.3 Pricing
    • 3.4.4 Reimbursement of Drugs

4. Indian Pharmaceutical Market: Discussions and Predictions 2019-2029

  • 4.1 Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume
  • 4.2 Indian Pharmaceuticals Market: Overall Revenue Forecast 2018-2029

5. Medical Treatment Needs in India, 2019-2029

  • 5.1 Disease Prevalence in India, 2019-2029
  • 5.2 Disease Incidence in India, 2019-2029
  • 5.3 Disease Mortality Rates in India, 2019-2029
    • 5.3.1 Top Causes of Death in India
    • 5.3.2 Top Causes of Death in India: Mortality Projections, 2019-2029

6. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2019-2029

  • 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2018
  • 6.2 Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2019-2029
  • 6.3 Infectious Disease Drugs: Overview, 2018
    • 6.3.1 Infectious Disease Drugs Market: Forecast, 2019-2029
    • 6.3.2 Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2018
    • 6.3.3 Lower Respiratory Tract Infections Among Leading Causes of Death
    • 6.3.4 Tuberculosis Still Rife in India
    • 6.3.5 Malaria, Risk and Opportunity
    • 6.3.6 HIV in India: Growing Therapeutic Area Worth Watching
    • 6.3.7 Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment
  • 6.4 Cardiovascular Therapeutics Segment: Overview, 2018
    • 6.4.1 Cardiovascular Disease - India's Leading Cause of Death, 2018
    • 6.4.2 Cardiovascular Drugs Market: Forecast, 2019-2029
  • 6.5 Gastro-Intestinal Therapeutic Segment: Overview, 2018
    • 6.5.1 Gastro-Intestinal Drugs Market: Forecast, 2019-2029
    • 6.5.2 Gastro-Intestinal Therapeutics in India: Challenges and Opportunities
    • 6.5.3 Drivers and Restraints for the Gastro-Intestinal Therapeutics Segment
  • 6.6 Respiratory Therapeutic Segment: Overview, 2018
    • 6.6.1 Respiratory Disease Drugs Market: Forecast, 2019-2029
    • 6.6.2 Drivers and Restraints for the Respiratory Therapeutics Segment
  • 6.7 Pain Relief / Analgesics Therapeutic Segment: Overview, 2018
    • 6.7.1 Pain Relief / Analgesics Drugs Market: Forecast, 2019-2029
    • 6.7.2 Drivers and Restraints for the Pain Relief/Analgesics Therapeutics Segment
  • 6.8 Diabetes Therapeutic Segment: Overview, 2018
    • 6.8.1 Diabetes Therapeutics Market: Forecast, 2019-2029
    • 6.8.2 Drivers and Restraints for the Diabetes Therapeutics Segment
  • 6.9 Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2018
    • 6.9.1 Vitamins / Minerals / Nutrients Therapeutics Market: Forecast, 2019-2029
    • 6.9.2 Vitamins / Minerals / Nutrients in India: Challenges and Opportunities
    • 6.9.3 Drivers and Restraints for the Vitamins / Minerals / Nutrients Therapeutics Segment
  • 6.10 Dermatological Therapeutic Segment: Overview, 2018
    • 6.10.1 Dermatological Therapeutics Market: Forecast, 2019-2029
    • 6.10.2 Drivers and Restraints for the Dermatological Therapeutics Segment
  • 6.11 Central Nervous System (CNS) Therapeutics: Overview, 2018
    • 6.11.1 CNS Drugs Market: Forecast, 2019-2029
    • 6.11.2 Intentional Injury Among the Top 10 Leading Causes of Death, 2018
    • 6.11.3 India's Aging Population: Driver for the CNS Segment
    • 6.11.4 Drivers and Restraints for the CNS Therapeutics Segment
  • 6.12 Gynaecological Treatment Market Overview: 2018
    • 6.12.1 Infant Mortality Still High in India
    • 6.12.2 Indian Gynaecological Treatments Market: Forecast, 2019-2029
    • 6.12.3 Drivers and Restraints for the Gynaecological Segment
  • 6.13 Other Pharmaceutical Products Market Overview: 2018
    • 6.13.1 Incidence of Cancer is Rising in India
    • 6.13.2 Indian Other Treatments Market: Forecast, 2019-2029

7. Indian Pharmaceutical Market: Leading Drug Types, 2019-2029

  • 7.1 Drug Types in the Indian Market: Overview, 2018
  • 7.2 Growth Forecasts for Leading Drug Types in India, 2019-2029
  • 7.3 Generic Drugs Dominate the Indian Pharmaceutical Market
    • 7.3.1 Indian Generics: Overview, 2018
    • 7.3.2 Indian Generic Drugs Market: Forecast, 2018-2029
    • 7.3.3 Branded Generics Preferred by Many Indian Patients
    • 7.3.4 Drivers and Restraints for the Generic Drug Market in India
  • 7.4 Indian Over-The-Counter (OTC) Drugs Market: Overview, 2018
    • 7.4.1 Indian OTC Market: Forecast, 2019-2029
    • 7.4.2 Drivers and Restraints of the Indian OTC Market
  • 7.5 Indian Patented Drugs Market: Overview, 2018
    • 7.5.1 Indian Patented Drugs Market: Forecasts, 2019-2029
    • 7.5.2 Drivers and Restraints for the Indian Patented Drugs Market
  • 7.6 Indian Biosimilar Drugs, 2018
    • 7.6.1 Indian Biosimilar Drugs Market: Forecast, 2019-2029
    • 7.6.2 A Number of Blockbuster Drugs Coming Off-Patent Over the Next Decade
    • 7.6.3 Drivers and Restraints of the Indian Biosimilar Drugs Market

8. The Leading Companies in the Indian Pharmaceuticals Market

  • 8.1 Indian Pharmaceuticals Market Overview
    • 8.1.1 Indian Pharmaceutical Patent Law and the Effect on Big Pharmaceutical Companies
  • 8.2 Top 50 Domestic Indian Pharmaceutical Companies, 2018
  • 8.3 Sun Pharmaceuticals Industries Limited
    • 8.3.1 Sun Pharma: Global Presence
      • 8.3.1.1 Sun Pharmaceutical Sales by Region, 2017
    • 8.3.2 Sun Pharmaceuticals Business Performance 2008-2017
    • 8.3.3 Sun Pharmaceutical: The Acquisition of Ranbaxy Laboratories is the Largest Ever Deal Made by an Indian Pharmaceutical Company
      • 8.3.3.1 Other Major M&A Activity
  • 8.4 Abbott Healthcare Private Limited (Abbott India)
    • 8.4.1 Abbott India: Business Performance 2007-2017
    • 8.4.2 Abbott India: Major and Recent M&A Activity
  • 8.5 Cipla Ltd.
    • 8.5.1 Cipla: Business Performance 2008-2017
    • 8.5.2 Cipla Ltd.: Major and Recent Activity
  • 8.6 Cadila Healthcare Limited
    • 8.6.1 Cadila: Business Performance 2008-2017
    • 8.6.2 Cadila Healthcare Revenue by Therapeutic Area 2017
  • 8.7 GlaxoSmithKline Pharmaceuticals Limited
    • 8.7.1 GlaxoSmithKline India: Business Performance 2008-2017
  • 8.8 Pfizer Limited., India
    • 8.8.1 Pfizer India: Business Performance 2008-2017
  • 8.9 Lupin
    • 8.9.1 Lupin: Business Performance 2008-2017
    • 8.9.2 Lupin Revenue by Therapeutic Area, 2017
  • 8.10 Sanofi India Limited
    • 8.10.1 Sanofi India Limited: Business Performance 2008-2017
    • 8.10.2 Sanofi India Limited Revenue by Business Segments, 2017
    • 8.10.3 Sanofi India Limited Revenue by Geographical Area, 2017
    • 8.10.4 Sanofi India Limited Recent Activities
  • 8.11 Intas Pharmaceuticals Limited
    • 8.11.1 Intas Pharmaceuticals Limited: Business Performance 2008-2017
  • 8.12 Dr. Reddy's Laboratories Ltd.
    • 8.12.1 Dr. Reddy's Laboratories Ltd: Business Performance 2008-2017
    • 8.12.2 Dr. Reddy's Laboratories Ltd. Revenue by Business Segments, 2017
    • 8.12.3 Dr. Reddy's Laboratories Ltd Global Generics Segment Revenue by Geographical Area, 2017
  • 8.13 Glenmark Pharmaceuticals Limited
    • 8.13.1 Glenmark Pharmaceuticals Limited: Business Performance 2008-2017
    • 8.13.2 Glenmark Pharmaceuticals Limited Revenue by Geographical Area, 2017
    • 8.13.3 Glenmark Pharmaceuticals Limited Recent Activities

9. Qualitative Analysis of the Indian Pharmaceuticals Market, 2018

  • 9.1 Indian Pharmaceutical Market: Drivers and Restraints
  • 9.2 SWOT Analysis of the Indian Pharmaceuticals Market
  • 9.3 Strengths
    • 9.3.1 Increasing Investment in the Healthcare System
    • 9.3.2 The Disease Burden and GDP Growing
    • 9.3.3 India's Population Set to Become the World's Largest by 2030
    • 9.3.4 India Popular for Pharmaceutical Outsourcing
  • 9.4 Weaknesses
    • 9.4.1 Stringent Pricing Regulations Hit the Indian Pharmaceuticals Market
    • 9.4.2 Poor Infrastructure Threatens to Hinder Market Potential
    • 9.4.3 Intense Competition Driving Down Drug Prices
  • 9.5 Opportunities
    • 9.5.1 Global Demand for Generics Rising
    • 9.5.2 National Rural Health Mission Driving Healthcare Access in Rural Areas
    • 9.5.3 Significant Investment from MNCs Expected
    • 9.5.4 Innovative Biotechnology Sector Set to Capitalise on Patent Expiries
  • 9.6 Threats
    • 9.6.1 Rise of Other Low-Cost Generic Exporters
    • 9.6.2 Will the Indian Government Stick to Increasing Healthcare Expenditure?
    • 9.6.3 Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals
  • 9.7 Porter's Five Forces Analysis of the Indian Pharmaceuticals Market
    • 9.7.1 Rivalry Among Competitors [High]
    • 9.7.2 Threat of New Entrants [Low]
    • 9.7.3 Power of Suppliers [Medium]
    • 9.7.4 Power of Buyers [High]
    • 9.7.5 Threat of Substitutes [Low]

10. Conclusion

  • 10.1 The Indian Pharmaceuticals Market: Growing Global Market Share
  • 10.2 Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent
  • 10.3 Commercial Drivers of the Indian Pharmaceuticals Market
  • 10.4 Commercial Restraints of the Indian Pharmaceuticals Market
  • 10.5 Concluding Remarks

11. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form